CD28 family receptor

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Drugs in Development, 2021 Market Report - Indications, Stage of Development, Mechanism of Action, Route of Administration and Molecules - ResearchAndMarkets.com

Retrieved on:

Wednesday, April 28, 2021

Health, General Health, Medical specialties, Branches of biology, Clusters of differentiation, Immunology, Medicine, Immune system, T cell, CD28, CD28 family receptor, Theralizumab

b'The "T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com\'s offering.\nT Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Drugs in Development, 2021 provides in depth analysis on T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted pipeline therapeutics.\nThe report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.

Key Points:

b'The "T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com\'s offering.\nT Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Drugs in Development, 2021 provides in depth analysis on T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted pipeline therapeutics.\nThe report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.\nAdditionally, the report provides an overview of key players involved in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics development and features dormant and discontinued projects.
The report analyses the pipeline products across relevant therapy areas under development targeting T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28).\nThe report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.\nThe report reviews T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.\nThe report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages.\nThe report features descriptive drug profiles for the pipeline products which includes, Product Description, Descriptive Mechanism of Action (MoA), Research and Development (R&D) brief, Licensing and Collaboration details & Other Developmental Activities.\nThe report reviews key players involved in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics and enlists all their major and minor projects.\nThe report assesses T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics based on Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.\nThe report summarizes all the dormant and discontinued pipeline projects.\nThe report reviews latest news and deals related to T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics.\n'

Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the AACR Annual Meeting 2021

Retrieved on:

Saturday, April 10, 2021

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the presentation of new data from multiple preclinical XmAb bispecific antibody programs and its preclinical IL-12-Fc cytokine program at the American Association for Cancer Research (AACR) Annual Meeting, being held virtually April 10-15, 2021.

Key Points:

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the presentation of new data from multiple preclinical XmAb bispecific antibody programs and its preclinical IL-12-Fc cytokine program at the American Association for Cancer Research (AACR) Annual Meeting, being held virtually April 10-15, 2021.
"In 2021, we anticipate submitting an IND for XmAb819, our lead XmAb 2+1 CD3 bispecific antibody targeting ENPP3, and initiating a Phase 1 study in early 2022.
Xencor engineered PD-L1 x CD28 bispecific antibodies to provide conditional co-stimulation of T cells, activating them when bound to tumor cells.
A PD-L1 x CD28 bispecific antibody, therefore, may promote CD28 co-stimulation and simultaneously block CD28's suppression by PD-L1.

Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data of Tumor-Targeted Immune Cell Agonists (TICAs™) in the Journal for ImmunoTherapy of Cancer

Retrieved on:

Tuesday, January 26, 2021

Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Medical specialties, Clinical medicine, Medicine, Oncology, Immunology, Immune system, Cancer immunotherapy, Immune checkpoint, Immunotherapy, CD137, Cancer immunology, CD28 family receptor

Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that an article highlighting preclinical studies of Bicycles novel, fully synthetic Bicycle systemic immune cell agonists and tumor-targeted immune cell agonists (TICAs) was published in the Journal for ImmunoTherapy of Cancer (JITC).

Key Points:

Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that an article highlighting preclinical studies of Bicycles novel, fully synthetic Bicycle systemic immune cell agonists and tumor-targeted immune cell agonists (TICAs) was published in the Journal for ImmunoTherapy of Cancer (JITC).
The article, titled Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist is available online via this link .
In contrast to immune checkpoint inhibitors, the use of antibodies as agonists of immune costimulatory receptors as cancer therapeutics has largely failed.
The article outlines the work Bicycle is undertaking to unlock a new method of cancer immunotherapy via small molecule agonism of TNF superfamily receptors.